RESUMEN
Objective To explore the clinical characters and the relationship between prognosis and treatment in childhood acute non-lymphocytic leukemia(ANLL).Method We summarized and analyzed the cases with acute non-lymphocytic leukemia in children patients from our hospital admission between Jan 2003 and Sep 2007.Results ①The M1,M2 subtype of childhood ANLL were about 37.1%;the clinical situation was various;extramedullary infiltration was not uncommon;②A totle complete remission(CR)rate was 68.6% and the CR rate of one course chemotherapy was 40.1%;③The CR rate of acute promyelocytic leukemia(APL)was 87.5% and a average of continues CR(CCR)was 33 months after the treatment of ATRA combined with As2O3;④Among five patients finished all the courses of high dose Ara-c(HDAra-c)intensification therapy,three were CCR over 36 months.Conclusion ①The CR rate of one course chemotherapy was correlated to the intensity of treatment;②The treatment of As2O3 can help to lower the relapse of APL and enhance the event-free survival(EFS);③The treatment of HDAra-c can help to increase the EFS rate of childhood ANLL.
RESUMEN
Objective To explore the effect of STI571 on the CD_~117 expression and differentiation of bone marrow mononuclear cells in patients with acute non-lymphocytic leukemia(ANLL). Methods CD_~117 expression before and after STI571 treatment in vitro was assayed by FACS, and the cell differentiation was observed by Giemsa and peroxidase staining. Results After different concentrations of STI571 treatment in vitro, there was different degrees of differentiation in granulocytes and monocytes from patients with ANLL. With the increase of STI571 concentration, the number of progranulocyte and promyelocyte gradually decreased, the number of myelocyte, metamyelocyte and monocyte increased, and the positive degree of peroxidase staining increased. CD_~117 expression significantly decreased after STI571 treatment compared with before it. Conclusion STI571 could induce leukemia cells of ANLL into terminal differentiation by inhibiting c-kit tyrosine kinase.
RESUMEN
By the application of hybridoma technique we have established 3 cell strains designated as 1 D 1, 1 C 2 and 1 D6, which all the strains secrete anti-acute nonlymphocytic leukemia M2-type monoclonal antibodies individually. These strains secrete the McAb steadily after passed on propagation over 11 months. The McAb secreted by these cell strains all give positive reactions with the leukemia cells from actue non-lymphocytic leukemia M2-type pationt, but not with cells from M1, M3, M4, and M5 type patients. These McAb also can not react with cells from chronic myelocytic leukemia and its acute transformation phase and acute lymphocytic leukemia patient. The McAb can not react with white cells from normal adults too. From the above metioned we may conclude that the McAb secreted by these cells possess a remarkable specificity. Therefore it is applicable for the immuno-typing diagnosis of acute non-lymphoc yt ic leukemia and researches on target directed therapeutics.